Compounds > 5-(2-bromovinyl)uridine
Page last updated: 2024-11-11

5-(2-bromovinyl)uridine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

5-(2-bromovinyl)uridine: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6478043
CHEMBL ID375035
SCHEMBL ID3084990
SCHEMBL ID3503357
MeSH IDM0137784

Synonyms (10)

Synonym
5-(2-bromovinyl)uridine
5-[(e)-2-bromovinyl]-1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidine-2,4-dione
bv-ribou
86391-68-6
5-((e)-2-bromo-vinyl)-1-(3,4-dihydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-1h-pyrimidine-2,4-dione
CHEMBL375035
5-[(e)-2-bromoethenyl]-1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
SCHEMBL3084990
SCHEMBL3503357
e-5-2-bromovinyl uridine

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" It showed good oral bioavailability in rats (68."( Synthesis and antiviral activity of novel anti-VZV 5-substituted uracil nucleosides with a cyclopropane sugar moiety.
Aoki, M; Iwayama, S; Mukai, C; Nakagawa, R; Nakazawa, H; Ohmura, Y; Okunishi, M; Onishi, T; Ono, N; Sekiyama, T; Suzuki, K; Tsuji, T, 2000)		0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (52)

Assay IDTitleYearJournalArticle
AID87295The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in HeLa cell culture by 50% in presence of 20 ug/m concentrations of 6-aminothymine1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID81371Inhibitory dose for HELF cell proliferation during 3-day treatment period1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
Synthesis and biological activities of 4-O-(difluoromethyl)-5-substituted-uracil nucleoside analogues.
AID156859The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in PRK cell culture by 50% in presence of 40 ug/mL concentrations of 6-aminothymine1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID44365Compound was evaluated for the cytotoxicity against human T-cell leukemia, CCRF-HSB-2 by using MTT assay.1999Bioorganic & medicinal chemistry letters, Mar-22, Volume: 9, Issue:6
Synthesis of novel 4'-C-methyl-pyrimidine nucleosides and their biological activities.
AID84256Compound was evaluated for the antiviral activity against Herpes simplex virus type 1 (HSV-1) VR-3 strain by using plaque reduction assay.1999Bioorganic & medicinal chemistry letters, Mar-22, Volume: 9, Issue:6
Synthesis of novel 4'-C-methyl-pyrimidine nucleosides and their biological activities.
AID87297The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in HeLa cell culture by 50% in presence of 4 ug/m concentrations of 6-aminothymine1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID66767The compound was tested for its antiviral activity against HSV-2 (196) virus in E6SM cell culture1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID66770The compound was tested for its antiviral activity against TK-HSV-1 (B2006) virus in E6SM cell culture1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID103155The compound was tested for its antiviral activity against HSV-1 (KOS) virus in M-21 (GM137) cell line,1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID66766The compound was tested for its antiviral activity against HSV-1 (McIntyre) virus in E6SM cell culture1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID42109The compound was tested for its antiviral activity against HSV-1 (KOS) virus in BS-C-1A cell line1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID87293The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in HeLa cell culture by 50% in presence of 100 ug/m concentrations of 6-aminothymine1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID217663Compound was evaluated for the antiviral activity against Varicella-Zoster virus (VZV) Oka strain by using plaque reduction assay.1999Bioorganic & medicinal chemistry letters, Mar-22, Volume: 9, Issue:6
Synthesis of novel 4'-C-methyl-pyrimidine nucleosides and their biological activities.
AID66800The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 50 ug/mL concentrations of benzylacyclouridine1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID66768The compound was tested for its antiviral activity against HSV-2 (G) virus in E6SM cell culture1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID66798The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 4 ug/m concentrations of 6-aminothymine1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID66794The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 20 ug/m concentrations of 6-aminothymine1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID66769The compound was tested for its antiviral activity against HSV-2 (Lyons) virus in E6SM cell culture1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID209957The compound was tested for its antiviral activity against HSV-1 (KOS) virus in T-21 (LR) cell line1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID156542The compound was tested for its antiviral activity against HSV-1 (KOS) virus in PRK cell line1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID66782The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 10 ug/mL dThd1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID83716Ability to reduce plaque formation of herpes simplex virus type 1 (HSV-1) by 50% in human embryonic lung fibroblast (HELF) cell cultures1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
Synthesis and biological activities of 4-O-(difluoromethyl)-5-substituted-uracil nucleoside analogues.
AID66787The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 100 ug/mL dThd1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID66793The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 10 ug/mL concentrations of benzylacyclouridine1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID66797The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 300 ug/mL dThd1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID156857The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in PRK cell culture by 50% in presence of 20 ug/mL concentrations of 6-aminothymine1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID106009Tested for Antiherpetic activity against VZV from clinical isolates of MRC-5 cell lines.(average of six isolates)2000Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2
Synthesis and antiviral activity of novel anti-VZV 5-substituted uracil nucleosides with a cyclopropane sugar moiety.
AID156855The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in PRK cell culture by 50% in presence of 100 ug/mL concentrations of 6-aminothymine1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID66796The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 30 ug/mL dThd1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID104933The compound was tested for its antiviral activity against HSV-1 (KOS) virus in MO cell line1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID66774The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in absence of dThd1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID87298The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in HeLa cell culture by 50% in presence of absence concentrations of 6-aminothymine1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID86514The compound was tested for its antiviral activity against HSV-1 (KOS) virus in HeLa cell line1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID66772The compound was tested for its antiviral activity against vesicular stomatitis virus in E6SM cell culture1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID156853The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in PRK cell culture absence concentrations of 6-aminothymine1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID66765The compound was tested for its antiviral activity against HSV-1 (KOS) virus in E6SM cell culture1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID84950Ability to reduce plaque formation of herpes simplex virus type 2 (HSV-2) by 50% in human embryonic lung fibroblast (HELF) cell cultures1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
Synthesis and biological activities of 4-O-(difluoromethyl)-5-substituted-uracil nucleoside analogues.
AID41208The compound was tested for its antiviral activity against HSV-1 (KOS) virus in BALB/3T3 cell line1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID81898The compound was tested for its antiviral activity against HSV-1 (KOS) virus in HEp-2M cell line1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID66932The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of absence of concentrations of 6-aminothymine1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID66764The compound was tested for its antiviral activity against HSV-1 (F) virus in E6SM cell culture1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID85253Compound was evaluated for the antiviral activity against Herpes simplex virus type 2 (HSV-2) MS strain by using plaque reduction assay.1999Bioorganic & medicinal chemistry letters, Mar-22, Volume: 9, Issue:6
Synthesis of novel 4'-C-methyl-pyrimidine nucleosides and their biological activities.
AID66931The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of absence of concentrations of benzylacyclouridine1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID65516The compound was tested for its antiviral activity against HSV-1 (KOS) virus in E1SM cell line1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID85246The compound was tested for its antiviral activity against HSV-1 (KOS) virus in HSF (VGS) cell line1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID63780The compound was tested for its antiviral activity against HSV-1 (KOS) virus in E6SM cell line1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID106007Tested for Antiherpetic activity against HSV-1 from Tomioka strain in MRC-5 cell lines.2000Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2
Synthesis and antiviral activity of novel anti-VZV 5-substituted uracil nucleosides with a cyclopropane sugar moiety.
AID66777The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 1 ug/mL dThd1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID66771The compound was tested for its antiviral activity against vaccinia virus in E6SM cell culture1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID216509The compound was tested for its antiviral activity against HSV-1 (KOS) virus in vero cell line1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID66792The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 100 ug/mL concentrations of 6-aminothymine1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
AID66795The concentration required to reduce the cytopathogenicity of HSV-1 (KOS) in E6SM cell culture by 50% in presence of 3 ug/mL dThd1986Journal of medicinal chemistry, Feb, Volume: 29, Issue:2
Synthesis and antiviral activity of (E)-5-(2-bromovinyl)uracil and (E)-5-(2-bromovinyl)uridine.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (40.00)18.7374
1990's1 (20.00)18.2507
2000's2 (40.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.74

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.74 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.54 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.74)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
thymine
[no description available]		1.9610pyrimidine nucleobase;
pyrimidone		Escherichia coli metabolite;
human metabolite;
mouse metabolite
bromouracil
Bromouracil: 5-Bromo-2,4(1H,3H)-pyrimidinedione. Brominated derivative of uracil that acts as an antimetabolite, substituting for thymine in DNA. It is used mainly as an experimental mutagen, but its deoxyriboside (BROMODEOXYURIDINE) is used to treat neoplasms.. 5-bromouracil : A pyrimidine having keto groups at the 2- and 4-positions and a bromo group at the 5-position. Used mainly as an experimental mutagen.		1.9610nucleobase analogue;
pyrimidines		mutagen
uridine
[no description available]		7.3820uridinesdrug metabolite;
fundamental metabolite;
human metabolite
bromodeoxyuridine
Bromodeoxyuridine: A nucleoside that substitutes for thymidine in DNA and thus acts as an antimetabolite. It causes breaks in chromosomes and has been proposed as an antiviral and antineoplastic agent. It has been given orphan drug status for use in the treatment of primary brain tumors.		2.3720pyrimidine 2'-deoxyribonucleosideantimetabolite;
antineoplastic agent
deoxyuridine
[no description available]		1.9610pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
thymine arabinoside
thymine arabinoside: selectively inhibits replication of herpes simplex virus		1.9710N-glycosyl compound
6-aminothymine
6-aminothymine: inhibits degradation of nucleosides (idoxuridine, thymidine) & pyrimidine bases		1.9610
edoxudin
[no description available]		1.9710pyrimidine 2'-deoxyribonucleoside
brivudine
brivudine: anti-herpes agent		2.6730
5-(2-bromovinyl)uracil
5-(2-bromovinyl)uracil: RN given refers to (E)-isomer		6.9610
acyclovir
Acyclovir: A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes.. acyclovir : An oxopurine that is guanine substituted by a (2-hydroxyethoxy)methyl substituent at position 9. Used in the treatment of viral infections.		2.39202-aminopurines;
oxopurine		antimetabolite;
antiviral drug
penciclovir
penciclovir : A member of the class of 2-aminopurines that is guanine in which the hydrogen at position 9 is substituted by a 4-hydroxy-3-(hydroxymethyl)but-1-yl group. An antiviral drug, it is administered topically for treatment of herpes labialis. A prodrug, famciclovir, is used for oral administration.		2102-aminopurines;
propane-1,3-diols		antiviral drug
ConditionIndicatedRelationship StrengthStudiesTrials
Herpes Simplex Virus Infection
[description not available]		01.9610
Herpes Simplex
A group of acute infections caused by herpes simplex virus type 1 or type 2 that is characterized by the development of one or more small fluid-filled vesicles with a raised erythematous base on the skin or mucous membrane. It occurs as a primary infection or recurs due to a reactivation of a latent infection. (Dorland, 27th ed.)		01.9610